ABBV Stock Overview
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide.
Snowflake Score | |
---|---|
Valuation | 3/6 |
Future Growth | 4/6 |
Past Performance | 1/6 |
Financial Health | 3/6 |
Dividends | 4/6 |
AbbVie Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$171.14 |
52 Week High | US$182.89 |
52 Week Low | US$135.85 |
Beta | 0.62 |
11 Month Change | -0.13% |
3 Month Change | 2.84% |
1 Year Change | 20.36% |
33 Year Change | 45.60% |
5 Year Change | 156.74% |
Change since IPO | 388.97% |
Recent News & Updates
AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
Jul 17AbbVie: A Hold Again (Rating Downgrade)
Jul 03Recent updates
AbbVie Q2 2024 Earnings Preview: Post Gonzalez Era Can Begin On Positive Note
Jul 17AbbVie: A Hold Again (Rating Downgrade)
Jul 03Earnings Tell The Story For AbbVie Inc. (NYSE:ABBV)
Jun 28AbbVie: 5 Reasons That Make A Buy Case
Jun 18Looking For Both Income And Growth? 4%-Yielding AbbVie Has You Covered
May 29Here's Why AbbVie (NYSE:ABBV) Can Manage Its Debt Responsibly
May 21AbbVie's Q1: Positive Surprise
Apr 26AbbVie: Great To Be Proven Wrong - Still Not A Buy
Apr 14AbbVie: Still Fits Buffett's 10x EBT Rule Well Despite Guidance Revision
Apr 08AbbVie: Strong Cash Flow Growth Fuels Dividend Growth
Mar 08Shareholder Returns
ABBV | US Biotechs | US Market | |
---|---|---|---|
7D | 0.7% | 0.3% | -0.7% |
1Y | 20.4% | 12.0% | 20.2% |
Return vs Industry: ABBV exceeded the US Biotechs industry which returned 12% over the past year.
Return vs Market: ABBV matched the US Market which returned 20.2% over the past year.
Price Volatility
ABBV volatility | |
---|---|
ABBV Average Weekly Movement | 3.1% |
Biotechs Industry Average Movement | 10.7% |
Market Average Movement | 5.9% |
10% most volatile stocks in US Market | 14.9% |
10% least volatile stocks in US Market | 2.9% |
Stable Share Price: ABBV has not had significant price volatility in the past 3 months.
Volatility Over Time: ABBV's weekly volatility (3%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2012 | 50,000 | Robert Michael | www.abbvie.com |
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn’s disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine.
AbbVie Inc. Fundamentals Summary
ABBV fundamental statistics | |
---|---|
Market cap | US$309.50b |
Earnings (TTM) | US$5.95b |
Revenue (TTM) | US$54.40b |
50.8x
P/E Ratio5.6x
P/S RatioIs ABBV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
ABBV income statement (TTM) | |
---|---|
Revenue | US$54.40b |
Cost of Revenue | US$16.77b |
Gross Profit | US$37.63b |
Other Expenses | US$31.68b |
Earnings | US$5.95b |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Jul 25, 2024
Earnings per share (EPS) | 3.37 |
Gross Margin | 69.17% |
Net Profit Margin | 10.94% |
Debt/Equity Ratio | 924.1% |
How did ABBV perform over the long term?
See historical performance and comparison